Purpose of this Study
We are doing this study to find out if an investigational drug called vimseltinib (the study drug) is a safe and effective option for people with active Chronic Graft Versus Host Disease (cGVHD).
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with moderate-to-severe cGVHD after receiving an allogeneic hematopoietic stem cell transplant
- Have symptoms that became worse despite at least 2 previous lines of systemic therapy
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will take the study drug at an assigned dose level. Participants will get a random assignment to different dose levels, and the study doctor can let you know what your assigned dose level is.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Deciphera DCC-3014-02-001: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior
Systemic Therapy
Systemic Therapy
Principal Investigator
Mitchell
Horwitz
Protocol Number
PRO00116796
NCT ID
NCT06619561
Phase
II
Enrollment Status
Pending Open to Enrollment